Longs promotes Vasos to executive VP and COO
WALNUT CREEK, Calif. Longs Drug has appointed Todd Vasos as the company’s new executive vice president and chief operating officer. He replaces Karen Stout, who left the company. In his new role, Vasos will be responsible for marketing, merchandising, construction and store operations.
Vasos joined Longs in 2001 as senior vice president of marketing. He was promoted to senior vice president and chief merchandising officer in 2005 and has played a key role in the rollout of Longs’ store remodels and its front-end re-merchandising. Prior to arriving at Longs, Vasos served in executive positions at Phar-Mor and Eckerd Drug.
Larry Gatta will fill Vasos’ position as senior vice president and chief merchandising officer. Gatta joined Longs in 2002 as vice president of marketing and has more than 25 years of experience including stints at Rite Aid, Phar-Mor and Giant Eagle. Linda Voracek is moving up to the role of vice president of marketing and is responsible for all front-end categories. Voracek joined the chain in 2003 after six years at Kmart.
Longs did not provide a reason for Stout’s departure. Stout joined Longs in 2006 after a serving for two years as executive vice president of merchandising at warehouse club chain BJs Wholesale.
St. Charles Pharmaceuticals receives grant for research on new analgesic
NEW ORLEANS St. Charles Pharmaceutical has announced that it has received funding for the first year of three for a research grant from the National Institute of Neurological Disorders and Stroke.
St. Charles Pharma is a Louisiana based company that will use the award, technically a Cooperative Small Business Phase II SBIR Grant for Translational Research, to fund the research of SCP-123, which the company is working hard to place into clinics. The award will also work in funding the preparation of the application to be submitted to the FDA.
SCP-123 is an analgesic that treats neuropathic pain, and according to published reports, offers greater pain reduction, reduced side effects and has the potential to also treat acute, migraine, post-operative and pediatric pain.
“We are excited. Dr. Narducy and his research team have now raised $6 million in NIH grant funding to support the Company’s drug development efforts,” John Koerner, St Charles’ chairman, stated. “If all goes well, SCP-123 could fill a large, unmet medical need and become a drug of first choice—a blockbuster—for the treatment of neuropathic pain. This grant award is a big plus toward mitigating development risk and making it all happen.”
FDA issues warnings to makers of misbranded STD drugs
ROCKVILLE, Md. The Food and Drug Administration on Thursday issued six warning letters to five U.S. companies and one foreign individual for marketing unapproved and misbranded drugs over the Internet indicated for the prevention and treatment of sexually transmitted diseases.
“The products pose a serious health threat to unsuspecting consumers who don’t know that these products are not FDA approved and have not been proven safe or effective,” stated Janet Woodcock, deputy commissioner for scientific and medical programs, chief medical officer, and acting director of the FDA’s Center for Drug Evaluation and Research. “STDs are very serious diseases and these products give consumers a false sense of security that they are protected from STDs.”
Some of these products, directed at U.S. consumers, falsely claim to have “FDA Approval” and some claim to be “more effective” than conventional medicine, the regulatory agency stated. The products are sold as Tetrasil, Genisil, Aviralex, OXi-MED, Imulux, Beta-mannan, Micronutrient, Qina, and SlicPlus.
Consumers who are currently using these products should stop their use immediately and consult their health care professional if they have experienced any adverse effects that they suspect are related to the use of any of these products.
The products claim to prevent or treat a variety of STDs, including herpes, chlamydia, human papilloma virus, cervical dysplasia and HIV/AIDS.
Consumers and health care professionals should notify the FDA of any complaints or problems associated with these products, the agency stated. These reports may be made to MedWatch, the FDA’s voluntary reporting program, by calling 800-FDA-1088, or electronically at www.fda.gov/medwatch/report.htm.